Scientists at Sanford Burnham Prebys Medical Discovery Institute, USA, have identified a combination of two anti-cancer compounds that shrank pancreatic tumours in mice – supporting the immediate evaluation of the drugs in a clinical trial.
U.S. Food and Drug Administration (FDA)-approved versions of the compounds are used today to treat certain leukaemias and solid tumours, including melanoma.
The study was published in Nature Cell Biology.
“The sad reality is that at present, pancreatic cancer therapy is lagging since there is no effective treatment for these tumours,” says Ze’ev Ronai, Ph.D., professor in Sanford Burnham Prebys’ tumour Initiation and Maintenance Program and senior author of the study.
“Our study identifies a potential treatment combination that can immediately be tested against these aggressive tumours. We are already meeting with oncologists at Oregon Health & Science University to discuss how to advance this discovery into clinical evaluation.”
Pancreatic cancer is one of the deadliest cancers.
It is often difficult to diagnose because symptoms – such as pain in the abdomen, yellow skin and eyes, and weight loss don’t typically occur until the disease is advanced.
Less than 10 percent of people with pancreatic cancer remain alive five years later.
More than 56,000 Americans are expected to receive a pancreatic cancer diagnosis in 2019, according to the American Cancer Society.
In the study, the scientists used a drug called L-asparaginase to starve pancreatic tumours of a key nutrient, asparagine – an amino acid required for protein synthesis.
Instead of dying, they found that the tumour turned on a stress response pathway that allowed the cancer cells to produce asparagine themselves.
The scientists then treated mice with a second drug that blocked the stress response pathway and shrank the pancreatic tumour.
L-asparaginase is FDA approved to treat certain leukemias; and the second drug, a MEK inhibitor, is approved for the treatment of solid tumours, including melanoma, a type of skin cancer.
“This research lays the basis for the inhibition of pancreatic tumour growth by a combined synergistic attack based on asparagine restriction and MAPK signalling inhibition,” says Eytan Ruppin, M.D., Ph.D., a study author and chief of the Cancer Data Science Library at the National Cancer Institute, part of the National Institutes of Health (NIH). “Our lab was able to further support these findings through a computational analysis of patient data.”
Rosalie C. Sears, Ph.D., a professor at Oregon Health & Science University added: “It’s clear we’re not going to find a single magic bullet that cures cancer but will instead need several drugs that target multiple vulnerabilities. This study identifies a promising dual treatment for pancreatic cancer – one of the deadliest cancers – and I look forward to seeing these drugs tested in patients.”
In the same study, the scientists showed that the two treatments also shrank melanoma tumours in mice.
Due to the large unmet clinical need in pancreatic cancer, the scientists have decided to focus on this cancer first.